Mereo Biopharma Group Plc ADR [NASDAQ: MREO] closed the trading session at $2.41.
The stocks have a year to date performance of -31.14 percent and weekly performance of -5.86 percent. The stock has been moved at -40.49 percent over the last six months. The stock has performed -1.63 percent around the most recent 30 days and changed -28.91 percent over the most recent 3-months.
If compared to the average trading volume of 1.22M shares, MREO reached to a volume of 2737157 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mereo Biopharma Group Plc ADR [MREO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MREO shares is $7.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MREO stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Mereo Biopharma Group Plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 27, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on December 06, 2024, representing the official price target for Mereo Biopharma Group Plc ADR stock. Previously, the target price had yet another raise to $8, while Robert W. Baird analysts kept a Outperform rating on MREO stock.
The Average True Range (ATR) for Mereo Biopharma Group Plc ADR is set at 0.16 The Price to Book ratio for the last quarter was 5.14, with the Price to Cash per share for the same quarter was set at 0.52.
MREO stock trade performance evaluation
Mereo Biopharma Group Plc ADR [MREO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.86. With this latest performance, MREO shares dropped by -1.63% in over the last four-week period, additionally sinking by -40.49% over the last 6 months – not to mention a drop of -18.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MREO stock in for the last two-week period is set at 40.95, with the RSI for the last a single of trading hit 42.03, and the three-weeks RSI is set at 40.31 for Mereo Biopharma Group Plc ADR [MREO]. The present Moving Average for the last 50 days of trading for this stock 2.74, while it was recorded at 2.40 for the last single week of trading.
Mereo Biopharma Group Plc ADR [MREO]: An insightful look at the core fundamentals
Mereo Biopharma Group Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.10.
Earnings per share (EPS) analysis for Mereo Biopharma Group Plc ADR [MREO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MREO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mereo Biopharma Group Plc ADR go to 44.97%.
Mereo Biopharma Group Plc ADR [MREO]: Institutional Ownership
There are presently around $74.43%, or 75.20%% of MREO stock, in the hands of institutional investors. The top three institutional holders of MREO stocks are: RUBRIC CAPITAL MANAGEMENT LP with ownership of 15.31 million shares, which is approximately 2.1506%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 11.79 million shares of the stock with an approximate value of $$42.45 million in MREO stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$33.42 million in MREO stock with ownership which is approximately 1.3043%.
